SCHEMBL5456838

SCHEMBL5456838

Fc1ccc(-c2nn3c(NC4CCCC4)cccc3c2-c2ccnc(NC3CCCC3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 1/20 0.51
GSK3B P49841 6/20 0.47
MAPK14 Q16539 5/20 0.47
CDK4 P11802 2/20 0.47
MAPK13 O15264 1/20 0.47
MAPK12 P53778 1/20 0.47
MAPK11 Q15759 1/20 0.47
MAPK10 P53779 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
MAPK1 P28482 1/20 0.44
MAPK8 P45983 1/20 0.44
MAPK9 P45984 1/20 0.44
CSNK1A1 P48729 1/20 0.44
CLK2 P49760 1/20 0.44
GSK3A P49840 1/20 0.44
CSNK1G2 P78368 1/20 0.44
TAOK1 Q7L7X3 1/20 0.44
MINK1 Q8N4C8 1/20 0.44
AURKB Q96GD4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5462491 0.99 CSNK1D (0.51) CSNK1DGSK3BMAPK14CDK4MAPK13
SCHEMBL6184465 0.93 GSK3B (0.55) CSNK1DGSK3BMAPK14
SCHEMBL6106593 0.91 TP53 (0.46) CSNK1DGSK3BMAPK14CDK4MAPK13
SCHEMBL6105435 0.91 MAPK10 (0.52) GSK3BMAPK14CDK4MAPK10MAPK8
SCHEMBL6183945 0.91 GSK3B (0.61) GSK3BMAPK14MAPK13MAPK12MAPK11
SCHEMBL6106878 0.91 TP53 (0.45) CSNK1DGSK3BMAPK14CDK4MAPK13
SCHEMBL6106829 0.91 TP53 (0.45) CSNK1DGSK3BMAPK14CDK4MAPK13
SCHEMBL6105772 0.90 CDK4 (0.44) CSNK1DGSK3BMAPK14CDK4MAPK10
SCHEMBL5453367 0.90 IKBKB (0.49) GSK3BCDK4MAPK10MAPK8MAPK9
SCHEMBL5462495 0.90 GSK3B (0.55) CSNK1DGSK3BMAPK14CDK4MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1377573-B1 PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2005-07-27 EP claimed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-7163940-B2 Pyrazolopyridinyl pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-01-16 US disclosed
US-7163940-B2 Pyrazolopyridinyl pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-01-16 US disclosed
EP-1377573-B1 PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2005-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287721-A1 Pyrazolopyridinyl pyridine CYP3A5, CYP2C19, CYP3A4 CSNK1D 411/4885GSK3B 2943/4885MAPK14 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.